Amplia Therapeutics Limited
ASX:ATX.AX
0.15 (AUD) • At close October 23, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) AUD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 4.453 | 1.189 | 1.983 | 1.534 | 0.034 | 0.05 | 0.58 | 1.798 | 2.263 | 0.03 | 0 | 0 |
| Cost of Revenue
| 0.442 | 0.073 | 0.003 | 0.001 | 0.001 | 0.002 | 0.02 | 0.037 | 0.568 | 0.238 | 0.167 | 0.237 |
| Gross Profit
| 4.011 | 1.116 | 1.98 | 1.533 | 0.033 | 0.049 | 0.56 | 1.761 | 1.695 | -0.208 | -0.167 | -0.237 |
| Gross Profit Ratio
| 0.901 | 0.938 | 0.998 | 1 | 0.977 | 0.968 | 0.965 | 0.979 | 0.749 | -6.852 | 0 | 0 |
| Reseach & Development Expenses
| 5.805 | 4.687 | 3.772 | 2.212 | 1.072 | 0.678 | 3.224 | 6.036 | 4.746 | 2.041 | 0.648 | 0.773 |
| General & Administrative Expenses
| 2.604 | 2.198 | 1.636 | 1.135 | 0.859 | 1.105 | 1.428 | 2.393 | 1.476 | 1.602 | 1.746 | 0.727 |
| Selling & Marketing Expenses
| 0.086 | 0.517 | 0.216 | 0.528 | 0.328 | 0.244 | 0.192 | 0.297 | 0.271 | 0.14 | 0.052 | 0.214 |
| SG&A
| 2.69 | 2.715 | 1.852 | 1.663 | 1.187 | 1.246 | 1.581 | 2.896 | 1.997 | 1.602 | 1.746 | 0.941 |
| Other Expenses
| -0.059 | 1.189 | 1.983 | 1.591 | 0.034 | 0.05 | 0.643 | 1.831 | 2.295 | 0.03 | 0.028 | 0 |
| Operating Expenses
| 8.436 | 7.402 | 5.624 | 3.874 | 2.258 | 1.925 | 4.806 | 8.932 | 6.743 | 5.429 | 4.088 | 2.58 |
| Operating Income
| -4.425 | -7.475 | -5.627 | -3.875 | -2.259 | -1.926 | -4.826 | -8.969 | -7.311 | -5.398 | -4.089 | -3.03 |
| Operating Income Ratio
| -0.994 | -6.285 | -2.837 | -2.527 | -66.004 | -38.165 | -8.316 | -4.988 | -3.23 | -178.107 | 0 | 0 |
| Total Other Income Expenses Net
| -0.078 | 0.084 | -0.001 | 0.06 | 0.005 | 0.006 | 0.528 | 0.095 | 0.105 | 0.03 | 0.028 | -0.358 |
| Income Before Tax
| -4.503 | -7.391 | -5.628 | -3.815 | -2.254 | -1.92 | -4.298 | -8.874 | -7.206 | -5.237 | -4.495 | -3.388 |
| Income Before Tax Ratio
| -1.011 | -6.213 | -2.837 | -2.488 | -65.846 | -38.048 | -7.406 | -4.935 | -3.184 | -172.787 | 0 | 0 |
| Income Tax Expense
| -4.438 | -1.148 | -1.983 | -1.534 | -0.034 | -0.05 | -0 | -1.798 | -2.263 | -0.162 | 0.521 | 0 |
| Net Income
| -4.503 | -6.242 | -3.644 | -2.281 | -2.219 | -1.87 | -4.298 | -7.076 | -4.943 | -5.237 | -4.495 | -3.388 |
| Net Income Ratio
| -1.011 | -5.248 | -1.837 | -1.488 | -64.846 | -37.048 | -7.406 | -3.935 | -2.184 | -172.787 | 0 | 0 |
| EPS
| -0.023 | -0.032 | -0.025 | -0.024 | -0.042 | -0.043 | -0.17 | -0.3 | -0.24 | -0.27 | -0.34 | -0.2 |
| EPS Diluted
| -0.023 | -0.032 | -0.025 | -0.024 | -0.042 | -0.043 | -0.17 | -0.3 | -0.24 | -0.27 | -0.34 | -0.2 |
| EBITDA
| -4.56 | -7.402 | -5.624 | -3.874 | -2.258 | -1.925 | -4.806 | -8.932 | -6.743 | -3.881 | -2.527 | -1.701 |
| EBITDA Ratio
| -1.024 | -6.223 | -2.836 | -2.526 | -65.981 | -38.133 | -8.282 | -4.967 | -2.979 | -128.048 | 0 | 0 |